190 filings
Page 5 of 10
424B5
1erq vdod349
29 May 20
Prospectus supplement for primary offering
4:11pm
424B5
uwgwa7yb 7sl3rbh
26 May 20
Prospectus supplement for primary offering
4:04pm
6-K
198fna0pzgm
26 May 20
Current report (foreign)
8:00am
6-K
pby70ong596v5k5
14 May 20
Current report (foreign)
9:06am
6-K
k8m 545ko
12 May 20
Current report (foreign)
4:18pm
6-K
xwijlt6ng
31 Mar 20
Current report (foreign)
9:01am
6-K
fz4df1
27 Feb 20
Current report (foreign)
12:00am
6-K
6fcnpzim
13 Jan 20
JP Morgan Healthcare Conference January 2020 – San Francisco
7:50am
6-K
7flh3tuu tu8u83uxzl
9 Jan 20
Current report (foreign)
8:00am
6-K
qastnv lvc88
9 Dec 19
Current report (foreign)
8:08am
6-K
pyja wj1f770
8 Nov 19
Current report (foreign)
5:18pm
424B5
i3p z3qjfhrl1b
8 Nov 19
Prospectus supplement for primary offering
5:14pm
424B5
e5czoj bhhiwdo4yu
6 Nov 19
Prospectus supplement for primary offering
5:26pm
6-K
urq3 m5p4ll
6 Nov 19
Current report (foreign)
9:24am
6-K
ziez22c11v7tf
24 Oct 19
Current report (foreign)
7:18am
6-K
eiguxbbcnz1t0i
15 Oct 19
Invitation to the extraordinary shareholders’ meeting
4:36pm
6-K
4ma8yxhcyl 5cf
1 Aug 19
First of two registration trials from Phase 3 program of efgartigimod in primary immune thrombocytopenia (ITP) patients expected to start in 2H19
6:17am
6-K
k9acs8jc6zt
28 May 19
Current report (foreign)
6:09am
6-K
6fn52qu sru
22 May 19
Current report (foreign)
6:10am